Neurological aspects of human parvovirus B19 infection: a systematic review.
Parvovirus B19 has been linked with various clinical syndromes including neurological manifestations. However, its role in the latter remains not completely understood. Although the last 10 years witnessed a surge of case reports on B19-associated neurological aspects, the literature data remains scattered and heterogeneous, and epidemiological information on the incidence of B19-associated neurological aspects cannot be accurately extrapolated. The aim of this review is to identify the characteristics of cases of B19-associated neurological manifestations. A computerized systematic review of existing literature concerning cases of B19-related neurological aspects revealed 89 articles describing 129 patients; 79 (61.2%) were associated with CNS manifestations, 41 (31.8%) were associated with peripheral nervous system manifestations, and 9 (7.0%) were linked with myalgic encephalomyelitis. The majority of the cases (50/129) had encephalitis. Clinical characteristic features of these cases were analyzed, and possible pathological mechanisms were also described. In conclusion, B19 should be included in differential diagnosis of encephalitic syndromes of unknown etiology in all age groups. Diagnosis should rely on investigation of anti-B19 IgM antibodies and detection of B19 DNA in serum or CSF. Treatment of severe cases might benefit from a combined regime of intravenous immunoglobulins and steroids. To confirm these outcomes, goal-targeted studies are recommended to exactly identify epidemiological scenarios and explore potential pathogenic mechanisms of these complications. Performing retrospective and prospective and multicenter studies concerning B19 and neurological aspects in general, and B19 and encephalitic syndromes in particular, are required.
Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Faraj
F
Barah
Sigrid
S
Whiteside
Sonia
S
Batista
Julie
J
Morris
D000914:Antibodies, Viral / Q000097:blood* / Q000134:cerebrospinal fluid; D002490:Central Nervous System / Q000187:drug effects / Q000503:physiopathology* / Q000821:virology; D004279:DNA, Viral / Q000097:blood* / Q000134:cerebrospinal fluid; D003937:Diagnosis, Differential; D004660:Encephalitis / Q000175:diagnosis / Q000503:physiopathology; D015673:Fatigue Syndrome, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D010322:Parvoviridae Infections / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D016732:Parvovirus B19, Human / Q000302:isolation & purification / Q000502:physiology; D010523:Peripheral Nervous System Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology* / Q000821:virology; D013256:Steroids / Q000627:therapeutic use
D000914:Antibodies, Viral; D004279:DNA, Viral; D016756:Immunoglobulins, Intravenous; D013256:Steroids